Autoimmune limbic encephalitis: a reversible form of rapidly progressive amnesia and seizures.

North Manchester General Hospital, Crumpsall, UK.
The journal of the Royal College of Physicians of Edinburgh 06/2010; 40(2):123-5. DOI: 10.4997/JRCPE.2010.208
Source: PubMed

ABSTRACT Many forms of rapidly progressive cognitive impairment are irreversible and rarely treatable. We present a case of autoimmune limbic encephalitis associated with voltage-gated potassium channel autoantibodies that led to rapid cognitive deterioration and bizarre behaviour, which subsequently improved following immunosuppressant therapy. The diagnosis of autoimmune limbic encephalitis needs to be considered in patients presenting with apparent viral encephalitis, in more unusual clinical situations in subjects with acute psychiatric illness and in cases of refractory epilepsy, particularly if there is evidence of amnesia. The diagnosis depends on the detection of specific antibodies directed against central nervous system targets. There can be a good response to immunosuppressant therapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Limbic encephalitis is one of the most common paraneoplastic neurological syndromes, which is mostly associated with small cell lung cancer, testicular tumors, and breast cancer. F-FDG PET/CT can have an important role both in the identification of limbic encephalitis itself and in the detection of the unknown malignancy that might have caused it. We report a case of a 57-year-old female patient with paraneoplastic limbic encephalitis, confirmed both by MRI and F-FDG PET/CT, and the concurrent identification of an unknown lung malignancy by whole-body PET/CT.
    Clinical nuclear medicine 03/2013; · 3.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the "level of evidence" criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized. J. Clin. Apheresis 28:145-284, 2013. © 2013 Wiley Periodicals, Inc.
    Journal of Clinical Apheresis 07/2013; 28(3):145-284. · 2.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies to voltage-gated potassium channels (VGKC) are associated with acquired neuromyotonia, limbic encephalitis, and Morvan's syndrome. The antibodies are often not associated with malignancy and have shown good clinical response to immunomodulatory therapies. A record review identified five patients with laboratory evidence of antibodies to VGKC who underwent plasma exchange (PE) as part of their immunosuppressive therapy for neurologic disease. Four of the patients presented with limbic encephalitis and one with neuromyotonia. Symptoms included memory impairment, seizures, and personality changes. All PE were 1.0 volume and were performed on an every-other-day schedule. Replacement fluid was 5% normal serum albumin except when a bleeding risk was identified and then fresh frozen plasma was added. Four of five patients were also receiving concurrent immunosuppressive therapy including corticosteroids. Of the five patients treated with PE, three had sustained improvement in symptoms for 6-17 months following PE. Two patients did not have signs of improvement at a limited follow-up. One patient had recurrence of her symptoms, which responded to additional PE. These cases, as well as the reports in the literature, suggest that PE could be a useful adjunctive therapy for patients with VGKC antibodies and neurologic symptoms. J. Clin. Apheresis 27:267-273, 2012. © 2012 Wiley Periodicals, Inc.
    Journal of Clinical Apheresis 04/2012; 27(5):267-73. · 2.27 Impact Factor


Available from